WO2008143255A1 - 細胞集団の製造方法 - Google Patents

細胞集団の製造方法 Download PDF

Info

Publication number
WO2008143255A1
WO2008143255A1 PCT/JP2008/059238 JP2008059238W WO2008143255A1 WO 2008143255 A1 WO2008143255 A1 WO 2008143255A1 JP 2008059238 W JP2008059238 W JP 2008059238W WO 2008143255 A1 WO2008143255 A1 WO 2008143255A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell population
cell
fibronectin
production
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/059238
Other languages
English (en)
French (fr)
Inventor
Mitsuko Ideno
Shusaku Yamashita
Keisuke Tomita
Nobuko Muraki
Fuyuko Takashima
Kinuko Nagamine
Fumiyo Sakai
Naoko Ashida
Akiko Kato
Tatsuji Enoki
Ikunoshin Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Priority to JP2009515246A priority Critical patent/JPWO2008143255A1/ja
Publication of WO2008143255A1 publication Critical patent/WO2008143255A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　工程（１）：Ｔ細胞を含有する細胞集団からＣＤ８陽性Ｔ細胞を除去、もしくはＣＤ４陽性Ｔ細胞を採取することにより培養に供する細胞集団を調製する工程、及び工程（２）：前記工程（１）で得られた細胞集団を、下記（Ａ）及び（Ｂ）の存在下で培養する工程〔（Ａ）フィブロネクチン、フィブロネクチンのフラグメント及びフィブロネクチンのフラグメントの混合物からなる群より選択される少なくとも１つ（Ｂ）ＣＤ３リガンド〕を包含することを特徴とする細胞集団の製造方法。当該製造方法により得られる細胞集団は、細胞医療による疾患の治療に極めて有用である。
PCT/JP2008/059238 2007-05-22 2008-05-20 細胞集団の製造方法 Ceased WO2008143255A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009515246A JPWO2008143255A1 (ja) 2007-05-22 2008-05-20 細胞集団の製造方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-135266 2007-05-22
JP2007135266 2007-05-22
JP2007272535 2007-10-19
JP2007-272535 2007-10-19

Publications (1)

Publication Number Publication Date
WO2008143255A1 true WO2008143255A1 (ja) 2008-11-27

Family

ID=40031951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/059238 Ceased WO2008143255A1 (ja) 2007-05-22 2008-05-20 細胞集団の製造方法

Country Status (3)

Country Link
JP (1) JPWO2008143255A1 (ja)
TW (1) TW200914613A (ja)
WO (1) WO2008143255A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142766A1 (en) * 2010-08-10 2013-06-06 Katsuyuki Dodo Production method for cell populations
JP2018038409A (ja) * 2010-02-03 2018-03-15 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
US10787642B2 (en) 2010-02-03 2020-09-29 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005179299A (ja) * 2003-12-22 2005-07-07 Hokkaido Technology Licence Office Co Ltd 改変標的化ｔ細胞の製造方法及び医薬
WO2007040105A1 (ja) * 2005-09-30 2007-04-12 Takara Bio Inc. Ｔ細胞集団の製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005179299A (ja) * 2003-12-22 2005-07-07 Hokkaido Technology Licence Office Co Ltd 改変標的化ｔ細胞の製造方法及び医薬
WO2007040105A1 (ja) * 2005-09-30 2007-04-12 Takara Bio Inc. Ｔ細胞集団の製造方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAVIS L.S. ET AL.: "Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules", J. IMMUNOL., vol. 145, no. 3, 1990, pages 785 - 793, XP002381603 *
IDENO M. ET AL.: "Kumikaetai Hito Fibronectin Fragment Shigeki ni yoru Kasseika CTL no Tairyo Expansion-ho", PROCEEDINGS OF THE JAPANESE CANCER ASSOCIATION, vol. 62ND, 25 August 2003 (2003-08-25), pages 175 + ABSTR.NO. 2144-OA *
IDENO M. ET AL.: "RetroNectin to Ko-CD3 Kotai no Kumiawase ni yotte Kakudai Baiyo sareta T-saibo Shudan wa NaiveT-saibo Tokuiteki na Hyogengata o Yusuru Saibo o Koritsu de Gan'yu shi, Taikai Kogen Ninshikino o Hakki suru", BIOTHERAPY (TOKYO), vol. 20, no. SUPPL. 1, 25 September 2006 (2006-09-25), pages 84 *
MATSUYAMA T. ET AL.: "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex", J. EXP. MED., vol. 170, no. 4, 1989, pages 1133 - 1148, XP003011562 *
MURAKI N. ET AL.: "RetroNectin o Kumiawaseta T-saibo Kakudai Baiyo (I); Kakudai Baiyo ga Anteika shi, NaiveT-saibo ga Kohiritsu de Zoshoku (T cell expansion using RetroNectin (I): Useful method to expand Tcells, characterized by high portion of NaiveT-like cells)", PROCEEDINGS OF THE JAPANESE CANCER ASSOCIATION, vol. 65TH, 28 August 2006 (2006-08-28), pages 330 + ABSTR. NO. P-707, XP003011558 *
NOJIMA Y. ET AL.: "VLA-4 mediates CD3-dependent CD4+ T cell activation via the CS1 alternatively spliced domain of fibronectin", J. EXP. MED., vol. 172, no. 4, 1990, pages 1185 - 1192 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018038409A (ja) * 2010-02-03 2018-03-15 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
US10787642B2 (en) 2010-02-03 2020-09-29 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
US12024717B2 (en) 2010-02-03 2024-07-02 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
US20130142766A1 (en) * 2010-08-10 2013-06-06 Katsuyuki Dodo Production method for cell populations
US9670459B2 (en) 2010-08-10 2017-06-06 Takara Bio Inc. Production method for cell populations

Also Published As

Publication number Publication date
JPWO2008143255A1 (ja) 2010-08-12
TW200914613A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2007002136A3 (en) Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
WO2008054825A3 (en) Mixed cell populations for tissue repair and separation technique for cell processing
WO2008024769A3 (en) Intensified perfusion production method
WO2013102084A3 (en) Fermentative production of alcohols
WO2008006038A3 (en) Methods and compositions for butanol production
WO2006136953A3 (en) Method of producing organotypic cell cultures
PL2274419T3 (pl) Sposoby wytwarzania mikromieszków włosowych i brodawek de novo i stosowanie ich w badaniach in vitro i przeszczepach in vivo
MX2009009970A (es) Generacion de bloques de construccion quimicos a partir de biomasa vegetal mediante la despolimerizacion selectiva.
WO2008090770A1 (ja) Ｌ－アミノ酸を生産する微生物及びｌ－アミノ酸の製造法
SG10201803982TA (en) Antibodies and processes for preparing the same
GB2428044A (en) Method of forming mesenchymal stem cells from embryonic stem cells
TW200741000A (en) Method of producing lymphocytes
WO2007143117A3 (en) Differentiation of primate pluripotent cells to hepatocyte-lineage cells
MX2012007117A (es) Metodo para cultivar celulas adherentes.
MY184072A (en) Increasing virus like particle yield in plants
WO2008150001A1 (ja) アディポクラスタ－
WO2008143255A1 (ja) 細胞集団の製造方法
WO2009071428A3 (de) Verfahren zur erzeugung von biogas unter verwendung eines gärsubstrats mit eingestellter ammoniumstickstoffkonzentration
WO2009106835A3 (en) Production process
WO2013012269A3 (ko) 전능성 줄기세포로부터 희소돌기아교 전구세포의 제조 방법
WO2010028632A3 (de) Verfahren zur herstellung von bakteriell synthetisierter cellulose und cellulosehaltigem material in flächiger form
WO2008111506A1 (ja) 遺伝子導入細胞調製方法
PL2207795T3 (pl) Sposób wytwarzania dojrzałego, rekombinowanego alergenu grupy I roztoczy
WO2008021502A3 (en) Methods and compositions for removing cells from collection material
WO2006119860A8 (de) Zellkultursystem sowie verfahren zur kultivierung einer zellkultur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764397

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009515246

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08764397

Country of ref document: EP

Kind code of ref document: A1